Huons Co., Ltd. (243070.KQ)
KRW 27400.0
(8.3%)
KRW 27400.0
(8.3%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 58.35 Billion KRW | -11.36% |
| 2022 | 65.82 Billion KRW | 2934.44% |
| 2021 | 2.16 Billion KRW | -94.2% |
| 2020 | 37.41 Billion KRW | 852.71% |
| 2019 | 3.92 Billion KRW | -43.12% |
| 2018 | 6.9 Billion KRW | -43.91% |
| 2017 | 12.3 Billion KRW | 2720.47% |
| 2016 | 436.34 Million KRW | 0.0% |
| 2014 | 5.49 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 61.7 Billion KRW | 5.74% |
| 2024 Q2 | 62.86 Billion KRW | 1.89% |
| 2023 Q4 | 58.35 Billion KRW | -10.23% |
| 2023 FY | 58.35 Billion KRW | -11.36% |
| 2023 Q1 | 65 Billion KRW | -1.26% |
| 2023 Q2 | 65 Billion KRW | 0.0% |
| 2023 Q3 | 65 Billion KRW | 0.0% |
| 2022 Q2 | 34.37 Billion KRW | 1370.29% |
| 2022 Q1 | 2.33 Billion KRW | 7.77% |
| 2022 FY | 65.82 Billion KRW | 2934.44% |
| 2022 Q4 | 65.82 Billion KRW | 32.67% |
| 2022 Q3 | 49.61 Billion KRW | 44.35% |
| 2021 Q2 | 36.36 Billion KRW | -5.43% |
| 2021 Q4 | 2.16 Billion KRW | -94.19% |
| 2021 Q1 | 38.45 Billion KRW | -0.47% |
| 2021 FY | 2.16 Billion KRW | -94.2% |
| 2021 Q3 | 37.33 Billion KRW | 2.67% |
| 2020 FY | 37.41 Billion KRW | 852.71% |
| 2020 Q4 | 38.63 Billion KRW | 572.0% |
| 2020 Q3 | 5.74 Billion KRW | -0.63% |
| 2020 Q2 | 5.78 Billion KRW | 1.01% |
| 2020 Q1 | 5.72 Billion KRW | 7.91% |
| 2019 FY | 3.92 Billion KRW | -43.12% |
| 2019 Q1 | 5.45 Billion KRW | -21.02% |
| 2019 Q4 | 5.3 Billion KRW | 1.25% |
| 2019 Q3 | 5.24 Billion KRW | -7.07% |
| 2019 Q2 | 5.64 Billion KRW | 3.46% |
| 2018 FY | 6.9 Billion KRW | -43.91% |
| 2018 Q3 | 12.51 Billion KRW | 0.6% |
| 2018 Q2 | 12.44 Billion KRW | 0.59% |
| 2018 Q4 | 6.9 Billion KRW | -44.86% |
| 2018 Q1 | 12.37 Billion KRW | 0.53% |
| 2017 Q2 | 12.17 Billion KRW | 47.89% |
| 2017 Q4 | 12.3 Billion KRW | 0.54% |
| 2017 FY | 12.3 Billion KRW | 2720.47% |
| 2017 Q1 | 8.23 Billion KRW | 1786.68% |
| 2017 Q3 | 12.24 Billion KRW | 0.54% |
| 2016 Q3 | 4.56 Billion KRW | 0.0% |
| 2016 Q4 | 436.34 Million KRW | -90.44% |
| 2016 FY | 436.34 Million KRW | 0.0% |
| 2014 FY | 5.49 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 988.75 Million KRW | -5801.354% |
| CMG Pharmaceutical Co., Ltd. | 19.06 Billion KRW | -206.074% |
| Celltrion Pharm, Inc. | 4.33 Billion KRW | -1246.544% |
| Huons Global Co., Ltd. | 66.94 Billion KRW | 12.837% |
| DongKook Pharmaceutical Co., Ltd. | 18.74 Billion KRW | -211.202% |
| Enzychem Lifesciences Corporation | 1.02 Billion KRW | -5592.683% |
| Humedix Co., Ltd. | 1.75 Billion KRW | -3224.163% |
| Boditech Med Inc. | 2.09 Billion KRW | -2678.651% |
| EuBiologics Co., Ltd. | 2.8 Billion KRW | -1983.929% |
| FutureChem Co.,Ltd | 2.61 Billion KRW | -2127.273% |
| BNC Korea Co., Ltd. | 301.69 Million KRW | -19241.031% |
| AptaBio Therapeutics Inc. | 13.56 Billion KRW | -330.01% |